CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving…
Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ETNEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- TG…
Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14…
PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming…
SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company…
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This…
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage…
PHAXIAM Provides Business and Financial UpdateFor the First Half of 2023 Conference call and webcast (English) on Monday, September 25,…
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial…